Press releases

Media contact: Stéphanie Bardon – communication@genethon.fr – 01.69.47.12.78

Genethon receives the 2012 Prix Galien France

(read more)

Genethon, member of the Biotherapies Institute for Rare Diseases

The Biotherapies Institute for Rare Diseases, a unique task force to accelerate therapeutic developments, includes 4 laboratories founded and supported by the AFM Telethon : the Institute of Myology, Genethon, I-Stem and Atlantic Gene Therapies (Nantes’ gene therapy research centre). (read more)

Alain Schwenck, an Expert on Pharmaceutical Prodcution, becomes Director of Genethon Bioprod

Alain Schwenck, 51, has joined Genethon as Director of Genethon Bioprod, the new site for the production of clinical grade-gene therapy medicines for the treatment of rare diseases, created by AFM-Telethon. (read more)

Fulvio Mavilio, the internationally acknowledged expert in gene therapy for rare diseases, is appointed as Genethon’s new Scientific Director

(read more)

Gene therapy : Encouraging results in a Phase I clinical trial in limb-girdle muscular dystrophy type 2C

(read more)

Genethon and Children’s Hospital Boston get FDA approval for a Wiskott Aldrich gene therapy trial

(read more)

Genethon and Wake Forest University School of Medicine (North Carolina) announce their collaboration for a preclinical gene therapy trial

Evry (France), March 8th, 2011 – Genethon (the not-for-profit biotherapy lab funded by the French Muscular Dystrophy Association (Association Française contre les Myopathies, AFM) with donations from France’s annual Telethon) and Wake Forest University School of Medicine (Winston Salem, North Carolina, USA) today… (read more)

Partnership for a gene therapy Clinical trial signed between Genethon and Children’s Hospital Boston

(read more)

bluebird bio and Généthon Announce Manufacturing Research Collaboration Centered on Lentiviral Vectors for Gene Therapy

(read more)

Innovative biotherapies and genetic eye diseases

(read more)

Généthon initiates a new clinical trial for a severe immune deficiency (Wiskott-Aldrich syndrome)

(read more)

Genethon appoints biopharma industry expert Frédéric Revah as Chief Executive

(read more)

An effective gene therapy approach for dysferlin deficiencies

(read more)

Thermo Fischer Scientific 2009 prize

(read more)

Gene therapy: Production of the first batch of HIV-derived vectors in Europe for use in a human clinical trial

Genethon, the laboratory created and funded by the AFM (French Association against Myopathies) using donations from Téléthon, today announced that it has produced, controlled and released a batch of lentiviral vectors derived from the human immunodeficiency (HIV) virus for a gene therapy trial in humans in a rare immune deficiency. The… (read more)